ES2997164T3 - 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile - Google Patents
1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile Download PDFInfo
- Publication number
- ES2997164T3 ES2997164T3 ES21739678T ES21739678T ES2997164T3 ES 2997164 T3 ES2997164 T3 ES 2997164T3 ES 21739678 T ES21739678 T ES 21739678T ES 21739678 T ES21739678 T ES 21739678T ES 2997164 T3 ES2997164 T3 ES 2997164T3
- Authority
- ES
- Spain
- Prior art keywords
- formula
- compound
- pyrrolidine
- benzyloxy
- carbonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382606 | 2020-07-07 | ||
| PCT/EP2021/068577 WO2022008477A1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2997164T3 true ES2997164T3 (en) | 2025-02-14 |
Family
ID=71607883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21739678T Active ES2997164T3 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12459891B2 (enExample) |
| EP (1) | EP4178945B1 (enExample) |
| JP (1) | JP7628716B2 (enExample) |
| KR (1) | KR20230035604A (enExample) |
| CN (1) | CN117545738A (enExample) |
| AU (1) | AU2021303440A1 (enExample) |
| BR (1) | BR112023000335A2 (enExample) |
| CA (1) | CA3185064A1 (enExample) |
| ES (1) | ES2997164T3 (enExample) |
| HR (1) | HRP20241527T1 (enExample) |
| HU (1) | HUE068953T2 (enExample) |
| IL (1) | IL299035B1 (enExample) |
| MA (1) | MA60250B1 (enExample) |
| MX (1) | MX2023000261A (enExample) |
| RS (1) | RS66215B1 (enExample) |
| SM (1) | SMT202400460T1 (enExample) |
| TW (1) | TWI893162B (enExample) |
| WO (1) | WO2022008477A1 (enExample) |
| ZA (1) | ZA202213708B (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
| DE19603510A1 (de) | 1996-02-01 | 1997-08-07 | Knoell Hans Forschung Ev | Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase |
| FI20011466A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| FI20030014A0 (fi) | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| FI20031018A0 (fi) | 2003-07-04 | 2003-07-04 | Orion Corp | Parannus aivovammasta toipumiseen |
| WO2005027934A1 (ja) | 2003-09-24 | 2005-03-31 | Nippon Kayaku Kabushiki Kaisha | プロリルオリゴペプチダーゼ阻害剤 |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| ES2302473B1 (es) | 2006-12-22 | 2009-06-12 | Universidad De Barcelona | Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos. |
| EP2730571A1 (en) * | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
-
2021
- 2021-07-06 AU AU2021303440A patent/AU2021303440A1/en active Pending
- 2021-07-06 RS RS20241253A patent/RS66215B1/sr unknown
- 2021-07-06 WO PCT/EP2021/068577 patent/WO2022008477A1/en not_active Ceased
- 2021-07-06 HR HRP20241527TT patent/HRP20241527T1/hr unknown
- 2021-07-06 MX MX2023000261A patent/MX2023000261A/es unknown
- 2021-07-06 TW TW110124773A patent/TWI893162B/zh active
- 2021-07-06 EP EP21739678.7A patent/EP4178945B1/en active Active
- 2021-07-06 HU HUE21739678A patent/HUE068953T2/hu unknown
- 2021-07-06 JP JP2022581707A patent/JP7628716B2/ja active Active
- 2021-07-06 CA CA3185064A patent/CA3185064A1/en active Pending
- 2021-07-06 SM SM20240460T patent/SMT202400460T1/it unknown
- 2021-07-06 CN CN202180047448.7A patent/CN117545738A/zh active Pending
- 2021-07-06 US US18/004,658 patent/US12459891B2/en active Active
- 2021-07-06 MA MA60250A patent/MA60250B1/fr unknown
- 2021-07-06 ES ES21739678T patent/ES2997164T3/es active Active
- 2021-07-06 BR BR112023000335A patent/BR112023000335A2/pt unknown
- 2021-07-06 KR KR1020237003988A patent/KR20230035604A/ko active Pending
-
2022
- 2022-12-12 IL IL299035A patent/IL299035B1/en unknown
- 2022-12-19 ZA ZA2022/13708A patent/ZA202213708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202213708B (en) | 2024-04-24 |
| IL299035A (en) | 2023-02-01 |
| TWI893162B (zh) | 2025-08-11 |
| JP7628716B2 (ja) | 2025-02-12 |
| SMT202400460T1 (it) | 2025-01-14 |
| EP4178945B1 (en) | 2024-08-28 |
| BR112023000335A2 (pt) | 2023-01-31 |
| US12459891B2 (en) | 2025-11-04 |
| AU2021303440A1 (en) | 2023-02-02 |
| CN117545738A (zh) | 2024-02-09 |
| EP4178945C0 (en) | 2024-08-28 |
| US20230250058A1 (en) | 2023-08-10 |
| WO2022008477A1 (en) | 2022-01-13 |
| EP4178945A1 (en) | 2023-05-17 |
| CA3185064A1 (en) | 2022-01-13 |
| HUE068953T2 (hu) | 2025-02-28 |
| MX2023000261A (es) | 2023-04-13 |
| JP2023533932A (ja) | 2023-08-07 |
| MA60250B1 (fr) | 2024-11-29 |
| TW202216689A (zh) | 2022-05-01 |
| KR20230035604A (ko) | 2023-03-14 |
| HRP20241527T1 (hr) | 2025-01-03 |
| IL299035B1 (en) | 2026-03-01 |
| RS66215B1 (sr) | 2024-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10611727B2 (en) | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | |
| ES3063182T3 (en) | The peptidomimetic compound (r)-2-amino-n-((s)-l-(((s)-5-amino-l-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide for use in the treatment of amyotrophic lateral sclerosis | |
| US8748656B2 (en) | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | |
| ES2766548T3 (es) | Inhibidores de gelatinasa y uso de los mismos | |
| EP4178945B1 (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| RU2841064C1 (ru) | 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил | |
| HK40084881A (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| HK40084881B (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| HK1214597B (en) | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | |
| HK1255029B (en) | Gelatinase inhibitors and use thereof |